isabelobrien, Author at European Medical Journal - Page 33 of 66

contract

Thomas J. Fuchs appointed as Lilly's first Chief AI Officer

Eli Lilly and Company appoints their first Chief AI Officer in Thomas J. Fuchs, to spearhead the strategic direction and leadership of AI.

The word spotlight on a blue background

Spotlight: September 2024

Catch up on all the biggest news to hit the pharmaceutical industry this September, including new appointments, mergers and acquisitions, approvals and more.

Doctors in a surgery room standing in a line

Lord Darzi’s report on the NHS: What pharma needs to know

For the pharmaceutical industry, this situation highlights ways to step in as partners in healthcare innovation and support the NHS during a turbulent time.

World Mental Health Day with Boehringer Ingelheim’s Nedim Pipic

Nedim Pipic, Senior Vice President and Global Therapeutic Area Head for Mental Health, Boehringer Ingelheim marks World Mental Health Day.

US scientists win Nobel Prize for Medicine for discovering microRNA

American researchers Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize in Physiology or Medicine for their pioneering discovery of microRNA.

world in hands

Gilead expands access to PrEP HIV candidate in 120 countries

A new licensing agreement from Gilead Sciences and six generic drug manufacturers is poised to transform HIV prevention efforts

AZ's Dr Sunil Verma on the next chapter in cancer care

Ever wondered what one of the world’s top oncology leaders believes to be the next big thing in cancer care? Find out in our interview AstraZeneca’s Dr Sunil Verma.

ViiV Healthcare's Jean-Bernard Simeon

ViiV Healthcare’s Jean-Bernard Simeon on ending the HIV epidemic

Join JB, ViiV Healthcare Europe to explore the HIV landscape in Europe, the UNAIDS plan to end the epidemic by 2030 and more in this podcast.

Coin stacks

Genentech acquires Regor’s next-gen CKD inhibitor portfolio

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth $850M.

Orange lungs on yellow background

Sanofi and Regeneron's allergy drug is first biologic for COPD

Sanofi and Regeneron have announced that dupilumab has received an FDA approval in COPD and an eosinophilic phenotype.